Verdinexor

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Verdinexor (KPT-335, KPT335) 是一种口服生物可利用的选择性核输出抑制剂 (SINE)，抑制核输出蛋白 Exportin 1 (XPO1/CRM1) 的功能以及 Jurkat 和犬 DLBCL 细胞的活力，IC50 为 8.7 nM分别为13.3nM和13.3nM。

Verdinexor (KPT-335, KPT335) is an orally bioavailable, selective inhibitor of nuclear export (SINE), inhibits the function of nuclear export protein Exportin 1 (XPO1/CRM1) and the viability of Jurkat and canine DLBCL cells with IC50 of 8.7 nM and 13.3 nM, respectively; induces apoptosis in CLBL1 cells and primary canine DLBCL cells; reduces influenza a virus replication in vitro and in vivo; also inhibits XPO1-mediated transport and reduces RSV replication in vitro, shows effectivity against RSV A and B strains and reduces viral replication following prophylactic or therapeutic administration.Influenza Phase 1 Clinical.

——

——

KPT-335 | KPT335

Membrane Transporter/Ion Channel

Exportin-1

Exportin-1

Infection

Influenza

1392136-43-4

441.337

C19H13F6N5O

>98% (HPLC)

DMSO: 82 mg/mL (185.4 mM); Ethanol: 9 mg/mL (20.3 mM) （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C(NNC1=NC=CC=C1)/C=C\N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2

(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyridin-2-ylmethyl)acrylamide

(-20℃)

With Ice Pack

≥ 2 years